<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861601</url>
  </required_header>
  <id_info>
    <org_study_id>111913</org_study_id>
    <nct_id>NCT00861601</nct_id>
  </id_info>
  <brief_title>Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease</brief_title>
  <official_title>TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is an open label, multi-centre, dose ranging study to assess efficacy, safety and
      pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Platelet Counts on Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Platelet Counts on Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Counts by Treatment Visit</measure>
    <time_frame>Day 1 (Baseline), Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)</time_frame>
    <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Counts by Post-Treatment Visit</measure>
    <time_frame>4 days post-treatment, 8 days post-treatment, and 15 days post-treatment</time_frame>
    <description>Platelet counts were measured by blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Counts at Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Counts by Treatment Visit</measure>
    <time_frame>Baseline, Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)</time_frame>
    <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Counts by Post-Treatment Visit</measure>
    <time_frame>4 days post-treatment, 8 days post-treatment, and 15 days post-treatment</time_frame>
    <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders on Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders on Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was &lt;80 x 10^9/Liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score &gt;=10 is classified as Class C (severe). Participants with a CP score &lt;10 were enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Counts on Day 15 by Sex</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the &quot;n's&quot; in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Counts on Day 15 by Age</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the &quot;n's&quot; in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</measure>
    <time_frame>Day 14, Day 15</time_frame>
    <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</measure>
    <time_frame>Day 14, Day 15</time_frame>
    <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</measure>
    <time_frame>Day 14, Day 15</time_frame>
    <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eltrombopag 12.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eltrombopag 25 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eltrombopag 37.5 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag 12.5 milligrams (mg) tablet</intervention_name>
    <description>eltrombopag 12.5 mg tablet once a day</description>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_label>low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag 25 mg tablet</intervention_name>
    <description>eltrombopag 25 mg tablet once a day</description>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_label>middle dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who agree to comply with protocol requirements and instructions and who
             provide signed and dated written informed consent.

          -  Male and female subjects, ≥20 years of age (at the time of informed consent) with
             chronic liver disease.

          -  Child-Pugh score &lt;=9.

          -  A baseline platelet count &lt;50,000/mcL.

          -  A baseline serum sodium level &gt;130 mEq/L.

          -  Haemoglobin concentration &gt;8 g/dL, stable for at least 4 weeks.

          -  A female is eligible to enter and participate in the study if she is of:

        Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including
        any female who:

          -  Has had a hysterectomy

          -  Has had a bilateral oophorectomy (ovariectomy)

          -  Has had a bilateral tubal ligation

          -  Is post-menopausal (demonstrate total cessation of menses for longer than one year)

        Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and
        within the 24 hour period prior to the first dose of investigational product and uses one
        of the following acceptable methods of contraception:

          -  Complete abstinence from intercourse.

          -  Any intrauterine device (IUD) with a documented failure rate of less than 1% per year.

          -  Double-barrier contraception (condom with spermicidal jelly, or diaphragm with
             spermicide).

          -  Male partner who is sterile (diagnosed by a qualified medical professional) prior to
             the female subject's study entry and is the sole sexual partner for that female.

          -  Oral contraceptive (combined).

          -  Subject has no physical limitation to ingest and retain oral medication.

        Exclusion Criteria:

          -  Subjects with known or suspected hypersensitivity, intolerance or allergy to any of
             the ingredients in eltrombopag tablets.

          -  Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or
             appropriate magnetic resonance imaging/computed tomography (MRI/CT) imaging
             techniques) within 3 months before the start of the study.

          -  History of arterial or venous thrombosis (including Budd-Chiari Syndrome),

        AND ≥ two of the following risk factors:

          -  hereditary thrombophilic disorders (e.g. antithrombinIII (ATIII) deficiency, etc.)

          -  hormone replacement therapy

          -  systemic contraception therapy (containing oestrogen)

          -  smoking

          -  diabetes

          -  hypercholesterolemia

          -  medication for hypertension or cancer

          -  Human Immunodeficiency Virus (HIV) infection.

          -  History of drug/alcohol abuse or dependence within 1 year prior to screening.

          -  Any disease condition associated with current active World Health Organization (WHO)
             Grade 3 or 4 bleeding.

          -  Active infection requiring systemic antibiotic therapy.

          -  Pregnant, nursing mothers, women who may be pregnant, or women who plan to become
             pregnant during the time of study participation.

          -  Treatment with platelet transfusion within 2 weeks prior to Day 1.

          -  Treatment with interferon within 4 weeks prior to Day 1.

          -  Treatment with an investigational drug within 30 days or five half-lives (whichever is
             longer) preceding the first dose of study medication.

          -  History of platelet agglutination abnormality.

          -  History of porphyria.

          -  Subjects who are deemed unsuitable for the study by the investigator (or
             subinvestigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>839-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oita</city>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol. 2012 Dec;47(12):1342-51. doi: 10.1007/s00535-012-0600-5. Epub 2012 Jun 8.</citation>
    <PMID>22674141</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <results_first_submitted>May 11, 2010</results_first_submitted>
  <results_first_submitted_qc>August 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2010</results_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eltrombopag 12.5 mg</title>
          <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Eltrombopag 25 mg</title>
          <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
        <group group_id="P3">
          <title>Eltrombopag 37.5 mg</title>
          <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eltrombopag 12.5 mg</title>
          <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Eltrombopag 25 mg</title>
          <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
        <group group_id="B3">
          <title>Eltrombopag 37.5 mg</title>
          <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="10.51"/>
                    <measurement group_id="B2" value="57.7" spread="8.69"/>
                    <measurement group_id="B3" value="66.3" spread="8.84"/>
                    <measurement group_id="B4" value="61.8" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian-Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants categorized into the indicated Child-Pugh (CP) Class</title>
          <description>The CP score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score &gt;=10 is classified as Class C (severe). Participants with a CP score &lt;10 were enrolled in the study</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Platelet Counts on Day 15</title>
        <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Full Analysis Set (FAS): all enrolled participants, excluding those who received no doses of eltrombopag during the treatment period, those without a baseline platelet assessment, and those without at least one on-therapy (scheduled or unscheduled) platelet assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts on Day 15</title>
          <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
          <population>Full Analysis Set (FAS): all enrolled participants, excluding those who received no doses of eltrombopag during the treatment period, those without a baseline platelet assessment, and those without at least one on-therapy (scheduled or unscheduled) platelet assessment.</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="8.2" upper_limit="41.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="28.2" upper_limit="79.8"/>
                    <measurement group_id="O3" value="60.0" lower_limit="29.3" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)</title>
        <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 mg of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &amp;lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &amp;lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)</title>
          <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
          <population>FAS</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="8.2" upper_limit="41.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="28.2" upper_limit="79.8"/>
                    <measurement group_id="O3" value="60.0" lower_limit="29.3" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0104</p_value>
            <p_value_desc>Linearity. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <p_value_desc>Saturation at the medium dose. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0808</p_value>
            <p_value_desc>Onset of response at the higher dose. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)</title>
        <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 mg of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &amp;lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &amp;lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)</title>
          <description>Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.</description>
          <population>FAS</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="8.2" upper_limit="41.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="28.2" upper_limit="79.8"/>
                    <measurement group_id="O3" value="60.0" lower_limit="29.3" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0116</p_value>
            <p_value_desc>Linearity. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0066</p_value>
            <p_value_desc>Saturation at the medium dose. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0846</p_value>
            <p_value_desc>Onset of response at the higher dose. This analysis is based on each participants' change in platelet count.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made because this analysis was exploratory.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Platelet Counts on Day 15</title>
        <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Platelet Counts on Day 15</title>
          <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.</description>
          <population>FAS</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.86" lower_limit="18.77" upper_limit="96.94"/>
                    <measurement group_id="O2" value="134.57" lower_limit="81.36" upper_limit="187.78"/>
                    <measurement group_id="O3" value="158.45" lower_limit="92.32" upper_limit="224.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Counts by Treatment Visit</title>
        <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
        <time_frame>Day 1 (Baseline), Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)</time_frame>
        <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group are missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Counts by Treatment Visit</title>
          <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
          <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group are missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
          <units>10^9/Liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="36" upper_limit="49"/>
                    <measurement group_id="O2" value="38.0" lower_limit="19" upper_limit="48"/>
                    <measurement group_id="O3" value="40.0" lower_limit="23" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="37" upper_limit="73"/>
                    <measurement group_id="O2" value="49.5" lower_limit="27" upper_limit="88"/>
                    <measurement group_id="O3" value="52.0" lower_limit="32" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="37" upper_limit="126"/>
                    <measurement group_id="O2" value="73.0" lower_limit="31" upper_limit="232"/>
                    <measurement group_id="O3" value="81.5" lower_limit="53" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Assessment Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="37" upper_limit="126"/>
                    <measurement group_id="O2" value="95.5" lower_limit="35" upper_limit="232"/>
                    <measurement group_id="O3" value="85.5" lower_limit="57" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Counts by Post-Treatment Visit</title>
        <description>Platelet counts were measured by blood draw.</description>
        <time_frame>4 days post-treatment, 8 days post-treatment, and 15 days post-treatment</time_frame>
        <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group are missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Counts by Post-Treatment Visit</title>
          <description>Platelet counts were measured by blood draw.</description>
          <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group are missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
          <units>10^9/Liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 days post-treatment, n=12, 13, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="41" upper_limit="173"/>
                    <measurement group_id="O2" value="100.0" lower_limit="38" upper_limit="271"/>
                    <measurement group_id="O3" value="109.0" lower_limit="59" upper_limit="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 days post-treatment, n=12, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="46" upper_limit="178"/>
                    <measurement group_id="O2" value="119.0" lower_limit="40" upper_limit="387"/>
                    <measurement group_id="O3" value="120.0" lower_limit="66" upper_limit="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days post-treatment, n=11, 13, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="36" upper_limit="157"/>
                    <measurement group_id="O2" value="87.0" lower_limit="29" upper_limit="382"/>
                    <measurement group_id="O3" value="97.0" lower_limit="59" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Counts at Day 22</title>
        <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
        <time_frame>Day 22</time_frame>
        <population>FAS. Participants in the 12.5 mg group have no data on Day 22 because they received the medication for only 14 days. Only 6 participants in the 25 mg group and 2 participants in the 37.5 mg group received the medication for an additional week, because they had a platelet count &lt;80 x 10^9/Liter on Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Counts at Day 22</title>
          <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.</description>
          <population>FAS. Participants in the 12.5 mg group have no data on Day 22 because they received the medication for only 14 days. Only 6 participants in the 25 mg group and 2 participants in the 37.5 mg group received the medication for an additional week, because they had a platelet count &lt;80 x 10^9/Liter on Day 15.</population>
          <units>10^9/Liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="82.5" lower_limit="35" upper_limit="126"/>
                    <measurement group_id="O3" value="72.5" lower_limit="57" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Counts by Treatment Visit</title>
        <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
        <time_frame>Baseline, Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)</time_frame>
        <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group is missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts by Treatment Visit</title>
          <description>Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
          <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group is missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="9.43"/>
                    <measurement group_id="O2" value="14.6" spread="11.80"/>
                    <measurement group_id="O3" value="15.4" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="26.13"/>
                    <measurement group_id="O2" value="54.0" spread="44.70"/>
                    <measurement group_id="O3" value="60.0" spread="48.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Assessment Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="26.13"/>
                    <measurement group_id="O2" value="64.0" spread="42.51"/>
                    <measurement group_id="O3" value="61.9" spread="47.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Counts by Post-Treatment Visit</title>
        <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
        <time_frame>4 days post-treatment, 8 days post-treatment, and 15 days post-treatment</time_frame>
        <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group is missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts by Post-Treatment Visit</title>
          <description>Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.</description>
          <population>FAS. The number of participants analyzed varies by visit, because the platelet count data on 4 days post-treatment in one participant in the 37.5 mg group is missing and the platelet count data post-specific therapies affecting the evaluation of efficacy are excluded from this efficacy analysis.</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 days post-treatment, n=12, 13, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="36.36"/>
                    <measurement group_id="O2" value="73.8" spread="50.14"/>
                    <measurement group_id="O3" value="97.6" spread="83.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 days post-treatment, n=12, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="40.50"/>
                    <measurement group_id="O2" value="100.9" spread="81.96"/>
                    <measurement group_id="O3" value="108.3" spread="81.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days post-treatment, n=11, 13, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="36.58"/>
                    <measurement group_id="O2" value="82.2" spread="83.13"/>
                    <measurement group_id="O3" value="83.0" spread="68.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders on Day 15</title>
        <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 15.</description>
        <time_frame>Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders on Day 15</title>
          <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 15.</description>
          <population>FAS</population>
          <units>percentage of responders</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="5.5" upper_limit="57.2"/>
                    <measurement group_id="O2" value="42.9" lower_limit="17.7" upper_limit="71.1"/>
                    <measurement group_id="O3" value="58.3" lower_limit="27.7" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders on Day 22</title>
        <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was &lt;80 x 10^9/Liter.</description>
        <time_frame>Day 22</time_frame>
        <population>FAS. Participants in the 12.5 mg group have no data on Day 22 because they received the medication for only 14 days. Only 6 participants in the 25 mg group and 2 participants in the 37.5 mg group received the medication for an additional week, because they had a platelet count &lt;80 x 10^9/Liter on Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders on Day 22</title>
          <description>A responder was defined as a participant with a platelet count within the target range (&gt;=80 x 10^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was &lt;80 x 10^9/Liter.</description>
          <population>FAS. Participants in the 12.5 mg group have no data on Day 22 because they received the medication for only 14 days. Only 6 participants in the 25 mg group and 2 participants in the 37.5 mg group received the medication for an additional week, because they had a platelet count &lt;80 x 10^9/Liter on Day 15.</population>
          <units>percentage of responders</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class</title>
        <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score &gt;=10 is classified as Class C (severe). Participants with a CP score &lt;10 were enrolled in the study.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS. The number of participants categorized as Class A or Class B is given in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class</title>
          <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score &gt;=10 is classified as Class C (severe). Participants with a CP score &lt;10 were enrolled in the study.</description>
          <population>FAS. The number of participants categorized as Class A or Class B is given in the category titles.</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Child-Pugh Class A, n=8, 8, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="32.51"/>
                    <measurement group_id="O2" value="44.5" spread="27.02"/>
                    <measurement group_id="O3" value="66.6" spread="60.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child-Pugh Class B, n=4, 6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="5.97"/>
                    <measurement group_id="O2" value="66.7" spread="61.93"/>
                    <measurement group_id="O3" value="50.8" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Counts on Day 15 by Sex</title>
        <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the &quot;n's&quot; in the category titles.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts on Day 15 by Sex</title>
          <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the &quot;n's&quot; in the category titles.</description>
          <population>FAS</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Female, n=4, 4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="31.16"/>
                    <measurement group_id="O2" value="83.5" spread="69.67"/>
                    <measurement group_id="O3" value="98.8" spread="65.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, n=8, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="15.03"/>
                    <measurement group_id="O2" value="42.2" spread="26.96"/>
                    <measurement group_id="O3" value="40.6" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Counts on Day 15 by Age</title>
        <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the &quot;n's&quot; in the category titles.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag 25 mg</title>
            <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
          <group group_id="O3">
            <title>Eltrombopag 37.5 mg</title>
            <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Counts on Day 15 by Age</title>
          <description>Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the &quot;n's&quot; in the category titles.</description>
          <population>FAS</population>
          <units>10^9/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years of age, n=7, 11, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="23.34"/>
                    <measurement group_id="O2" value="40.2" spread="24.50"/>
                    <measurement group_id="O3" value="49.8" spread="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years of age, n=5, 3, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="30.82"/>
                    <measurement group_id="O2" value="104.7" spread="71.32"/>
                    <measurement group_id="O3" value="67.3" spread="59.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
        <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.</description>
        <time_frame>Day 14, Day 15</time_frame>
        <population>PK Parameter Population: all participants from whom a PK sample was obtained and analyzed and whose PK parameter data was evaluated. One of the 12 participants took a prohibited medication that might have decreased the absorption of eltrombopag during the treatment period and was hence excluded from the PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
          <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.</description>
          <population>PK Parameter Population: all participants from whom a PK sample was obtained and analyzed and whose PK parameter data was evaluated. One of the 12 participants took a prohibited medication that might have decreased the absorption of eltrombopag during the treatment period and was hence excluded from the PK Parameter Population.</population>
          <units>nanograms/milliliter (ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3412.999" lower_limit="2549.0060" upper_limit="4569.8448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
        <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.</description>
        <time_frame>Day 14, Day 15</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
          <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.</description>
          <population>PK Parameter Population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.444" lower_limit="2.4593" upper_limit="4.8226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
        <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.</description>
        <time_frame>Day 14, Day 15</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag 12.5 mg</title>
            <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg</title>
          <description>Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.</description>
          <population>PK Parameter Population</population>
          <units>hours * ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65244.180" lower_limit="46617.4188" upper_limit="91313.5730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65235.699" lower_limit="46748.123" upper_limit="91034.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time period of detecting adverse events (AEs) and serious adverse events (SAEs) was from the start of eltrombopag (Day 1) treatment to 15 days post-treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eltrombopag 12.5 mg</title>
          <description>Participants received 12.5 milligrams (mg) of eltrombopag once daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Eltrombopag 25 mg</title>
          <description>Participants received 25 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
        <group group_id="E3">
          <title>Eltrombopag 37.5 mg</title>
          <description>Participants received 37.5 mg of eltrombopag once daily for 14 days. Participants with a platelet count &lt;80 x 10^9/Liter on Day 15 received eltrombopag for an additional week if the participant agreed to it and the investigator considered it appropriate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

